Clinical trial · Interventional
Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma
NCT03807947CI-TRIAL-00036602unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this prospective, randomized study is to compare TRA vs TFA for superselective embolization of HCC using bland microparticles performed by multiple operators. In particular, main objectives are to compare: 1. the success rates of TRA and TFA including crossing over events between techniques 2. the inter-operator outcomes in terms of time to complete the vascular access and the vessel catheterization 3. access-related adverse events 4. patient preference and reported discomfort
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radial TAE - Bland embolization with 40-100 Microparticles | Procedure | — | UNRESOLVED |
| Transfemoral TAE - Bland embolization with 40-100 Microparticles | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Radial access
- interventionNames
- Procedure: Radial TAE - Bland embolization with 40-100 Microparticles
- type
- ACTIVE_COMPARATOR
- label
- Transfemoral Access
- interventionNames
- Procedure: Transfemoral TAE - Bland embolization with 40-100 Microparticles
Primary outcomes (1)
- measure
- Pain and discomfort during and after procedures
- timeFrame
- 24 hours after intervention
- description
- Questionnaire with four questions with 5 a points scale describing pain and discomfort during and after procedure, where 0 is the minimum and 4 the maximum.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion criteria: * patients affected by HCC with indication to TAE from a multidisciplinary team discussion. Exclusion criteria * TAE for other malignancies or bleedings; * Pregnancy.
References
Publications (1)
- BACKGROUNDIezzi R, Pompili M, Posa A, Annicchiarico E, Garcovich M, Merlino B, Rodolfino E, Di Noia V, Basso M, Cassano A, Barone C, Gasbarrini A, Manfredi R, Colosimo C. Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study. J Vasc Interv Radiol. 2017 Sep;28(9):1234-1239. doi: 10.1016/j.jvir.2017.06.022. Epub 2017 Jul 27. PMID 28757286